„This agreement with the U.S. government will help accelerate the development of our long-term antibody combination, which has the potential to achieve an immediate and lasting effect in both the prevention and treatment of COVID-19 infections,” said Pascal Soriot, CEO of AstraZeneca, in a press release. „We will evaluate the LAAB combination in different settings, from prophylaxis to inpatient to outpatient care, with a focus on supporting the most vulnerable.” AstraZeneca has committed to supply 400 million doses under its first delivery contracts. The U.S. deal – via HHS`s BARDA agency – follows a British pact presented on Sunday for 100 million total doses. This gives the U.S. delivery of about 300 million doses of vaccine starting this fall. Together, the agreements mark recent commitments to enable global access to the vaccine, including for low- and middle-income countries, beyond AstraZeneca`s recent partnerships with Britain and the United States. The company is setting up a series of parallel supply chains around the world to support profitless global access during the pandemic and has so far secured production capacity for two billion doses of vaccine.
The agreement with CEPI and Gavi is also the first advanced commitment in the market through the access to COVID-19 Tools (ACT) accelerator, a global cooperation between philanthropic, multilateral, private and civil society partners. The mechanism will work to accelerate the development, production and equal access to new COVID-19 tools worldwide, including in low- and middle-income countries. Cepi will lead vaccine design and production and Gavi will lead procurement within the global mechanism. AstraZeneca, based in Cambridge, England, said it had reached agreements for at least 400 million doses of the vaccine and ensured production capacity of 1 billion doses, with the first deliveries set to begin in September. Eli Lilly said Friday that he had not signed an agreement with Operation Warp Speed. The company today entered into a $750 million agreement with CEPI and Gavi to support the production, supply and distribution of 300 million doses of the vaccine, which will begin delivery by the end of the year. In addition, AstraZeneca has entered into a licensing agreement with SII to supply one billion doses to low- and middle-income countries, with the obligation to provide 400 million by the end of 2020. These agreements apply with companies and governments, as the company moves closer to previous results of a clinical trial at the end of the phase. . .